Onder Gizem, Ozdemir Ozkan, Taylan Fulya, Canpolat Cengiz, Yalcin Koray, Erbey Fatih, Sozmen Banu Oflaz, Asarcikli Fikret, Bayhan Turan, Akcabelen Yunus Murat, Yarali Nese, Ozbek Namik Yasar, Bozkaya Ikbal Ok, Kacar Dilek, Ergun Berk, Akkus Alper, Albayrak Davut, Ince Elif, Demirsoy Ugur, Ozdemir Gul Nihal, Dogru Omer, Aras Seda, Aydin Eylul, Unal Busra, Amanvermez Ufuk, Dogan Ozlem Akgun, Akyoney Sezer, Sayitoglu Muge, Nordgren Ann, Bugra Agaoglu Nihat, Ozbek Ugur, Ng Ozden Hatirnaz
Department of Biochemistry and Molecular Biology, Health Sciences Institute, Acıbadem Mehmet Ali Aydınlar University, Istanbul, Türkiye.
Rare Diseases and Orphan Drugs Application and Research Center (ACURARE), Rare Diseases and Orphan Drugs Application and Research Center (ACURARE), Acıbadem University, Istanbul, Türkiye.
Front Genet. 2025 Sep 9;16:1624306. doi: 10.3389/fgene.2025.1624306. eCollection 2025.
Leukemia is the most common cancer in children, and 10%-15% of patients with leukemia/lymphoma carry pathogenic germline cancer-predisposing variants. Identifying these variants is critical for understanding the genetic predisposition and optimizing clinical management.
We performed germline short-read sequencing in 36 individuals from 20 families with suspected leukemia/lymphoma predisposition, including 20 index cases, 9 affected relatives, and 7 unaffected members.
We identified 13 clinically relevant germline variants in known cancer predisposition genes including and . Notably, we uncovered novel candidate variants in , and , which was supported by segregation analysis, consanguinity patterns, and secondary malignancy phenotypes. Several index cases exhibited striking familial cancer syndromes involving both hematologic and solid tumors, with progression from ALL to AML or glioma. Deep clinical-genomic correlation enabled reclassification of variants and refined diagnostic and therapeutic decision-making in multiple cases. The patients were referred to genetic counseling for surveillance of carriers and risk assessment for various family members.
These findings emphasize the clinical utility of germline testing in pediatric hematologic cancers by providing novel insights into the predisposition to leukemia/lymphoma and contributing to treatment regimens, donor selection, and diagnostic refinement, particularly in populations with high consanguinity.
白血病是儿童最常见的癌症,10% - 15%的白血病/淋巴瘤患者携带致病性种系癌症易感变异。识别这些变异对于理解遗传易感性和优化临床管理至关重要。
我们对来自20个疑似白血病/淋巴瘤易感家庭的36名个体进行了种系短读测序,包括20名索引病例、9名患病亲属和7名未患病成员。
我们在已知的癌症易感基因中鉴定出13个与临床相关的种系变异,包括[具体基因1]和[具体基因2]。值得注意的是,我们在[具体基因3]、[具体基因4]和[具体基因5]中发现了新的候选变异,分离分析、近亲婚配模式和继发性恶性肿瘤表型支持了这一发现。一些索引病例表现出显著的家族性癌症综合征,涉及血液系统和实体肿瘤,从急性淋巴细胞白血病进展为急性髓细胞白血病或神经胶质瘤。深入的临床-基因组相关性分析使得变异重新分类,并在多个病例中优化了诊断和治疗决策。这些患者被转介至遗传咨询门诊,以便对携带者进行监测,并对不同家庭成员进行风险评估。
这些发现强调了种系检测在儿童血液系统癌症中的临床应用价值,为白血病/淋巴瘤的易感性提供了新的见解,并有助于治疗方案的制定、供体选择和诊断细化,特别是在近亲婚配率高的人群中。